Antibodies targeting talaromyces marneffei mp1p protein and methods of use thereof
US-2024199726-A1 · Jun 20, 2024 · US
US9933433B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9933433-B2 |
| Application number | US-201414452122-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 5, 2014 |
| Priority date | Sep 12, 2006 |
| Publication date | Apr 3, 2018 |
| Grant date | Apr 3, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention provides an antibody binding specifically to Cynomolgus IgG characterized by not binding to Human IgG, and a method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against said drug antibody (anti-drug antibody, ADA) in a sample of a monkey species using a double antigen bridging immunoassay.
Opening claim text (preview).
The invention claimed is: 1. A monoclonal antibody that binds to Cynomolgus IgG and does not bind to human IgG, wherein the monoclonal antibody is produced by a hybridoma cell line deposited with the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under Accession Nos. DSM ACC 2799, DSM ACC 2800, DSM ACC 2801, DSM ACC 2802 or DSM ACC 2803. 2. A hybridoma cell line producing a monoclonal antibody that binds to Cynomolgus IgG and does not bind to human IgG, wherein the hybridoma cell line is deposited with the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under Accession Nos. DSM ACC 2799, DSM ACC 2800, DSM ACC 2801, DSM ACC 2802 or DSM ACC 2803. 3. A composition comprising at least two monoclonal antibodies, wherein the at least two monoclonal antibodies are produced by two or more hybridoma cell lines selected from the group consisting of DSM ACC 2799, DSM ACC 2800, DSM ACC 2801, DSM ACC 2802 and DSM ACC 2803. 4. A method for the immunological determination of an immune complex (DA/ADA complex) of a drug antibody (DA) and an antibody against the drug antibody (ADA) in a monkey species sample using a double antigen bridging assay, the method comprising: incubating the sample with a capture antibody and a tracer antibody; wherein one of the capture or tracer antibody is a monoclonal antibody that binds to Cynomolgus IgG, does not bind to human IgG, and is produced by a hybridoma cell line selected from the group consisting of DSM ACC 2799, DSM ACC 2800, DSM ACC 2801, DSM ACC 2802 and DSM ACC 2803; and wherein the other of the capture or tracer antibody is an antibody that binds to human IgG; and detecting formation of a sandwich complex of capture antibody, DA/ADA complex, and tracer antibody; wherein the amount of sandwich complex formed is correlated to the concentration of and DA/ADA complex in the sample. 5. The method of claim 4 , wherein the monkey species sample is preincubated with a predetermined amount of the drug antibody.
Constant or Fc region; Isotype · CPC title
specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor · CPC title
Purification, fragmentation · CPC title
from primates, e.g. man · CPC title
Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.